Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ebolavirus | 11 | 2025 | 48 | 4.370 |
Why?
|
| Hemorrhagic Fever, Ebola | 8 | 2025 | 31 | 3.480 |
Why?
|
| Antibodies, Viral | 15 | 2025 | 295 | 3.030 |
Why?
|
| Marburgvirus | 5 | 2025 | 8 | 2.810 |
Why?
|
| Ebola Vaccines | 5 | 2022 | 8 | 2.760 |
Why?
|
| Viral Vaccines | 5 | 2025 | 36 | 2.650 |
Why?
|
| Vaccines, Synthetic | 7 | 2025 | 78 | 2.070 |
Why?
|
| Vaccines, Subunit | 5 | 2025 | 34 | 1.740 |
Why?
|
| Glycoproteins | 5 | 2025 | 127 | 1.220 |
Why?
|
| Microspheres | 3 | 2024 | 49 | 1.130 |
Why?
|
| Adjuvants, Immunologic | 5 | 2022 | 117 | 1.120 |
Why?
|
| Antibodies, Neutralizing | 5 | 2024 | 118 | 1.090 |
Why?
|
| Filoviridae | 1 | 2025 | 2 | 0.950 |
Why?
|
| Filoviridae Infections | 1 | 2025 | 2 | 0.950 |
Why?
|
| Marburg Virus Disease | 2 | 2025 | 3 | 0.940 |
Why?
|
| Viral Envelope Proteins | 3 | 2025 | 90 | 0.900 |
Why?
|
| Flavivirus | 1 | 2024 | 16 | 0.840 |
Why?
|
| Antigens, Viral | 1 | 2024 | 50 | 0.830 |
Why?
|
| Aedes | 1 | 2024 | 42 | 0.820 |
Why?
|
| Animals | 18 | 2025 | 16694 | 0.780 |
Why?
|
| Immunoassay | 5 | 2025 | 69 | 0.770 |
Why?
|
| Immunoglobulin G | 4 | 2025 | 253 | 0.600 |
Why?
|
| Dogs | 1 | 2019 | 201 | 0.590 |
Why?
|
| Viremia | 1 | 2018 | 44 | 0.580 |
Why?
|
| Cell Line | 4 | 2025 | 1416 | 0.560 |
Why?
|
| Macaca fascicularis | 3 | 2023 | 64 | 0.530 |
Why?
|
| Viral Matrix Proteins | 1 | 2017 | 18 | 0.520 |
Why?
|
| Immunization | 3 | 2022 | 93 | 0.510 |
Why?
|
| Viral Proteins | 1 | 2017 | 196 | 0.460 |
Why?
|
| Mice | 8 | 2025 | 6490 | 0.450 |
Why?
|
| Mice, Inbred BALB C | 4 | 2020 | 686 | 0.420 |
Why?
|
| Drosophila | 2 | 2025 | 150 | 0.410 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2025 | 456 | 0.390 |
Why?
|
| Aluminum Hydroxide | 2 | 2020 | 8 | 0.320 |
Why?
|
| Female | 9 | 2025 | 23980 | 0.310 |
Why?
|
| Immunity, Humoral | 2 | 2020 | 26 | 0.290 |
Why?
|
| Vaccination | 2 | 2022 | 332 | 0.290 |
Why?
|
| Immunity, Cellular | 2 | 2020 | 73 | 0.290 |
Why?
|
| Drug Stability | 2 | 2025 | 127 | 0.260 |
Why?
|
| Democratic Republic of the Congo | 2 | 2025 | 6 | 0.250 |
Why?
|
| Primates | 2 | 2022 | 38 | 0.240 |
Why?
|
| Drug Storage | 1 | 2025 | 28 | 0.230 |
Why?
|
| Humans | 8 | 2025 | 42113 | 0.230 |
Why?
|
| Water | 2 | 2023 | 314 | 0.210 |
Why?
|
| Sudan | 1 | 2023 | 3 | 0.210 |
Why?
|
| Vaccines, Combined | 1 | 2023 | 11 | 0.210 |
Why?
|
| Cell Culture Techniques | 1 | 2024 | 151 | 0.200 |
Why?
|
| Respiratory Tract Infections | 1 | 2022 | 36 | 0.190 |
Why?
|
| Protein Subunits | 1 | 2022 | 93 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 301 | 0.190 |
Why?
|
| Macaca | 1 | 2022 | 36 | 0.180 |
Why?
|
| Antibody Formation | 1 | 2022 | 75 | 0.180 |
Why?
|
| Male | 5 | 2025 | 22745 | 0.170 |
Why?
|
| Vero Cells | 2 | 2019 | 109 | 0.170 |
Why?
|
| Infant, Newborn | 1 | 2024 | 960 | 0.170 |
Why?
|
| Liberia | 1 | 2019 | 13 | 0.160 |
Why?
|
| Vaccines | 1 | 2020 | 64 | 0.150 |
Why?
|
| Seroepidemiologic Studies | 1 | 2019 | 71 | 0.150 |
Why?
|
| Guinea Pigs | 1 | 2019 | 144 | 0.150 |
Why?
|
| Serologic Tests | 1 | 2019 | 45 | 0.150 |
Why?
|
| West Nile Fever | 1 | 2019 | 64 | 0.140 |
Why?
|
| Dengue | 1 | 2019 | 100 | 0.140 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 1554 | 0.130 |
Why?
|
| Drosophila melanogaster | 1 | 2018 | 189 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2019 | 733 | 0.130 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2019 | 51 | 0.120 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 53 | 0.090 |
Why?
|
| Serine Endopeptidases | 1 | 2011 | 48 | 0.090 |
Why?
|
| Freeze Drying | 2 | 2021 | 29 | 0.080 |
Why?
|
| Dengue Virus | 1 | 2011 | 89 | 0.080 |
Why?
|
| West Nile virus | 1 | 2011 | 74 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2011 | 189 | 0.080 |
Why?
|
| Renin-Angiotensin System | 1 | 2022 | 44 | 0.050 |
Why?
|
| Trehalose | 1 | 2022 | 5 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 78 | 0.050 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2022 | 4 | 0.050 |
Why?
|
| Polysorbates | 1 | 2022 | 10 | 0.050 |
Why?
|
| Peroxides | 1 | 2022 | 21 | 0.050 |
Why?
|
| Emulsions | 1 | 2022 | 35 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2025 | 1728 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 72 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2019 | 90 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 522 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 602 | 0.030 |
Why?
|
| Young Adult | 1 | 2025 | 4928 | 0.030 |
Why?
|
| Adolescent | 1 | 2025 | 5949 | 0.030 |
Why?
|
| RNA Helicases | 1 | 2011 | 19 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2011 | 168 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2011 | 232 | 0.020 |
Why?
|
| Middle Aged | 1 | 2025 | 11790 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2011 | 491 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2011 | 560 | 0.020 |
Why?
|
| Adult | 1 | 2025 | 13437 | 0.020 |
Why?
|